Home Reagents Clinical Chemistry Reagents Benzodiazepine assay
Quality Guranteed Fast Delivery ad for support

Benzodiazepine assay

Product Method Size Catalog Price Quantity
Benzodiazepine assay Homogenous EIA R1 2 x 16.9ml , R2 2 x 8ml DA4009 $647.20
Shipping costs will be added at the checkout stage, click here for charges.
  • Format
    Liquid ready to use
  • Assay Range
  • Working Stability 15-25 °C
  • Working Stability 2-8 °C
    28 days
Request Kit Insert

Intended Use

The Benzodiazepine assay is an in vitro diagnostic reagent. For the qualitative and semi-quantitative analysis of Benzodiazepines in human urine. The cut-off for the qualitative application is 200ng/ml. This product is suitable for use on the RX Series instruments, which includes the Rx Daytona and the Rx Imola.

This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method.

Clinical Significance

The benzodiazepine family has a diverse chemical structure which gives rise to a range of physio-chemical and pharmacological properties. They form a large group and are used as sedatives and in the treatment of anxiety. It is estimated that over 50 benzodiazepine drugs are in common use world-wide with approximately a dozen marketed within a given country. Benzodiazepines are strongly associated with opioid users.

They are usually taken orally (although intravenous and intramuscular routes are also used) and as would be expected from such a diverse group, the pharmacological effects are broad and are also related with the absorption rate. In general, they are extensively metabolized by dealkylation, hydroxylation, oxidation and glucuronidation in the liver.

Some metabolites have biological activity; for example nordiazepam from diazepam and oxazepam from temazepam. Detection of benzodiazepines and their metabolites in urine can be used as an indication for use of benzodiazepines.


The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity.

In the absence of drug in the sample, benzodiazepine-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. However, when free drug is present in the sample, antibody would bind to free drug; the unbound benzodiazepine-labeled G6PDH then exhibits its maximal enzyme activity.

Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at 340 nm.